GSK plc reported Q1 2024 sales of £7.4 billion, up 10% overall, with specialty medicines and vaccines driving significant growth—16% and 17% respectively—while forecasting 2024 turnover growth of 5-7%. The filing reflects optimism about pipeline progress and includes a Q1 dividend of 15p, with an expected full-year dividend of 60p, accompanied by a positive sentiment regarding the company’s financial outlook.